Compare Campbell Soup Co. (CPB) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Summit Therapeutics Inc — how do they compare? Campbell Soup Co. trades at $21.91 (market cap $6.59B), while Summit Therapeutics Inc trades at $15.01 (market cap $12.01B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Campbell Soup Co. pays a 7.06% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| CPB | SMMT | |
|---|---|---|
Market Cap | $6.59B | $12.01B |
Sector | Consumer Staples | Health |
52-Week High | $34.03 | $29.32 |
52-Week Low | $20.00 | $13.05 |
Enterprise Value | $13.20B | $11.43B |
Dividend Yield | 7.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's (CPB) trades at $22.15, up 0.36% with neutral technical signals. The stock shows modest valuation metrics with P/E of 10.85 and P/S of 0.67, while recent earnings show mixed results with Q1 2026 beating expectations. Revenue growth remains stable at $10.25B for 2025, though profit margins have compressed from historical levels. The company maintains strong cash flow generation and recently launched new product innovations including protein soups and gluten-free options.
CPB offers value investors an attractive 7% dividend yield and reasonable valuation, but faces margin pressure and competitive headwinds. Analyst consensus leans cautious with 58.6% hold ratings, though recent product launches and cost initiatives provide potential catalysts. Key risks include ongoing margin compression and consumer spending sensitivity in the current economic environment.
Summit Therapeutics (SMMT) trades at $15.30, showing modest daily gains of 0.33%. The stock faces bearish technical signals with negative cash flows and substantial losses (-$1.08B net income in 2025). Recent developments include the sale of Phase III asset ridinilazole and positive clinical trial results for ivonescimab. Analyst sentiment remains optimistic with 67% buy ratings and a $15.57 consensus target, though financial metrics show concerning profitability with -270.95% ROE.
SMMT presents a high-risk, catalyst-driven opportunity with binary outcomes dependent on clinical success. The company's heavy reliance on ivonescimab development creates significant upside potential but also substantial execution risk. Negative cash flow trends and persistent losses require careful monitoring of upcoming Q2 2026 earnings and clinical milestones for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
